CompoAtlas

JaroBurn

Food supplement declared in France, decision dated 31 October 2026

JaroBurn (JaroBurn) is a food supplement declared in France. Status: declared in France, may be marketed. 2 rules of use apply to its ingredients (limits and warnings).

Brand
JaroBurn
Food business operator placing the product on the market
URGENTE & DILIGENTE - UNIPESSOAL LDA
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules par jour
Directions for use
Adultes : prendre 2 gélules par jour au cours d’un repas, avec un grand verre d’eau.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Pregnant women
Objectives stated by the manufacturer (these are not authorised claims)
Weight management / Slimming

Declaration 381026, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Camellia sinensis (L.) KuntzeFeuilleExtrait sec hydroalcoolique266.6 mg
Vaccinium macrocarpon AitonBaieExtrait sec hydroalcoolique100 mg
Zingiber officinale RoscoeRacineExtrait sec hydroalcoolique66.6 mg
Matricaria chamomilla L.FleurExtrait sec hydroalcoolique33.2 mg

Substances

NamePer day
caféine40 mg

Other active ingredients

NamePer day
Fibres de pommenot declared
L-Carnitine L-Tartratenot declared

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Réservé aux adultes. Ne pas dépasser la dose journalière recommandée. Contient de la caféine : 40 mg par dose journalière de 2 gélules. Contient un extrait de thé vert. Ne doit pas être consommé si vous prenez le même jour d’autres produits contenant du thé vert. Ne doit pas être consommé par les femmes enceintes ou allaitantes et par les enfants de moins de 18 ans. Ne doit pas être consommé à jeun. Ne pas consommer une quantité journalière égale ou supérieure à 800 mg de (-)-épigallocatéchine-3-gallate (EGCG). Teneur en EGCG : 26,6 mg par dose journalière. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Tenir hors de portée des jeunes enfants. Ne pas utiliser si l’opercule de sécurité est endommagé ou manquant.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium macrocarpon Aiton
    Read the warning, when it applies and the studies cited

    CRANBERRY - VACCINIUM MACROCARPON

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    DRIED CRANBERRY JUICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

  • Zingiber officinale Roscoe
    Read the warning, when it applies and the studies cited

    GINGER - ZINGIBER OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 19 December 2025

  • Matricaria chamomilla L.
    Read the warning, when it applies and the studies cited

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).

    Cautions and warnings

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Health Canada monograph dated 19 December 2025

    German Chamomile - Matricaria Chamomilla Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 31 January 2025

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal

    Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 29 May 2026

  • caféine
    Read the warning, when it applies and the studies cited

    CAFFEINE

    Route of administration: Oral (Higdon and Frei 2006)

    Cautions and warnings

    Applies to products providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    Sources cited by Health Canada (7)
    • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
    • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
    • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
    • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
    • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
    • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
    • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Applies to products providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    Sources cited by Health Canada (1)
    • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Review article

    Applies to products providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    Sources cited by Health Canada (8)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Case report
    • Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Randomised trial
    • FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
    • Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Randomised trial
    • NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
    • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Case report
    • Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.

    Contraindications

    Applies to products providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    Sources cited by Health Canada (7)
    • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
    • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
    • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
    • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
    • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
    • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
    • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    Sources cited by Health Canada (2)
    • Hinrichs R, Hunzelmann N, Ritzkowsky A, Zollner TM, Krieg T, Scharffetter-Kochanek K. Caffeine hypersensitivity. Allergy 2002;57(9):859-860. PubMed Case report
    • Infante S, Baeza ML, Calvo M, De Barrio M, Rubio M, Herrero T. Anaphylaxis due to caffeine. Allergy 2003;58(7):681-682. PubMed Case report

    Applies to products providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    Sources cited by Health Canada (1)
    • Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.

    Applies to products providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    Sources cited by Health Canada (3)
    • IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
    • Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Review article
    • Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Review article

    Condition of application: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : JaroBurn

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line